Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) have been assigned a consensus recommendation of “Buy” from the eleven analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $22.57.
Several equities analysts have recently commented on DRNA shares. Cowen restated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, July 2nd. Zacks Investment Research upgraded shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Tuesday, July 16th. ValuEngine upgraded shares of China Southern Airlines from a “sell” rating to a “hold” rating in a report on Tuesday, June 11th. SunTrust Banks decreased their price objective on shares of Dicerna Pharmaceuticals to $20.00 and set a “buy” rating on the stock in a report on Thursday, May 16th. Finally, B. Riley set a $24.00 price objective on shares of Dicerna Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, July 3rd.
In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv sold 1,600,000 shares of the stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $12.50, for a total transaction of $20,000,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 19.85% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its holdings in shares of Dicerna Pharmaceuticals by 4.3% in the 1st quarter. Rhumbline Advisers now owns 70,078 shares of the biopharmaceutical company’s stock valued at $1,027,000 after purchasing an additional 2,886 shares in the last quarter. Candriam Luxembourg S.C.A. raised its holdings in shares of Dicerna Pharmaceuticals by 53.5% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 447,500 shares of the biopharmaceutical company’s stock valued at $4,784,000 after purchasing an additional 156,000 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Dicerna Pharmaceuticals by 46.0% in the 4th quarter. BlackRock Inc. now owns 4,331,228 shares of the biopharmaceutical company’s stock valued at $46,300,000 after purchasing an additional 1,364,155 shares in the last quarter. American International Group Inc. raised its holdings in shares of Dicerna Pharmaceuticals by 17.6% in the 4th quarter. American International Group Inc. now owns 35,409 shares of the biopharmaceutical company’s stock valued at $379,000 after purchasing an additional 5,291 shares in the last quarter. Finally, Marshall Wace North America L.P. raised its holdings in shares of Dicerna Pharmaceuticals by 261.6% in the 1st quarter. Marshall Wace North America L.P. now owns 17,886 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 12,939 shares in the last quarter. Institutional investors own 85.76% of the company’s stock.
Shares of DRNA stock traded down $0.68 during trading hours on Tuesday, hitting $15.10. The company had a trading volume of 248,963 shares, compared to its average volume of 351,525. The business’s fifty day moving average is $14.55. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. Dicerna Pharmaceuticals has a fifty-two week low of $9.31 and a fifty-two week high of $17.98.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.16). Dicerna Pharmaceuticals had a negative return on equity of 52.17% and a negative net margin of 1,284.93%. The company had revenue of $3.11 million during the quarter, compared to analyst estimates of $10.59 million. As a group, research analysts predict that Dicerna Pharmaceuticals will post -1.35 EPS for the current fiscal year.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Featured Story: What are earnings reports?
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.